Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Arnd Nusch"'
Autor:
Diana Lüftner, Cosima Brucker, Thomas Decker, Peter Fasching, Thomas Göhler, Christian Jackisch, Jan Janssen, Andreas Köhler, Kerstin Lüdtke-Heckenkamp, Marion van Mackelenbergh, Frederik Marmé, Arnd Nusch, Beate Rautenberg, Toralf Reimer, Marcus Schmidt, Rudolf Weide, Pauline Wimberger, Naiba Nabieva, Christian Roos, Achim Wöckel
Publikováno v:
Cancer Research. 82:P1-18
Background: Ribociclib (RIB; a selective CDK4/6 inhibitor) + endocrine therapy (ET; aromatase inhibitor or fulvestrant along with ovarian suppression in pre- and perimenopausal patients [pts]) received USFDA and EMA approval for pre-, peri- and postm
Autor:
Peter A. Fasching, Cosima Brucker, Thomas Decker, Anne Engel, Thomas Göhler, Christian Jackisch, Jan Janssen, Andreas Köhler, Kerstin Lüdtke-Heckenkamp, Diana Lüftner, Marion van Mackelenbergh, Frederik Marmé, Arnd Nusch, Beate Rautenberg, Toralf Reimer, Marcus Schmidt, Rudolf Weide, Pauline Wimberger, Christian Roos, Achim Wöckel
Publikováno v:
Cancer Research. 83:P4-01
Background: Ribociclib in combination with endocrine therapy (ET) has demonstrated survival benefits in a broad patient population with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast c
Autor:
Christian Jackisch, Cosima Brucker, Thomas Decker, Anne Engel, Peter A. Fasching, Thomas Göhler, Jan Janssen, Andreas Köhler, Kerstin Lüdtke-Heckenkamp, Diana Lüftner, Marion van Mackelenbergh, Frederik Marmé, Arnd Nusch, Beate Rautenberg, Toralf Reimer, Marcus Schmidt, Rudolf Weide, Pauline Wimberger, Christian Roos, Achim Wöckel
Publikováno v:
Cancer Research. 83:P4-01
Background: Ribociclib (RIB) plus endocrine therapy (ET) has demonstrated a statistically significant survival benefit across the three phase 3 MONALEESA (ML) trials, irrespective of menopausal status, line of therapy, or combination partner. RIBANNA
Autor:
Marcus Schmidt, Diana Lüftner, Christian Jackisch, Achim Wöckel, Christian Roos, Jan Janssen, Toralf Reimer, Jörg Falbrede, Rudolf Weide, Oliver Hoffmann, C Brucker, Frederik Marmé, Andreas Köhler, Kerstin Lüdtke-Heckenkamp, Thomas Decker, Arnd Nusch, Peter A. Fasching, Thomas Göhler, Helmut Forstbauer
Publikováno v:
Cancer Research. 81:PS10-16
Background: In MONALEESA-3 and MONALEESA-7 trials, ribociclib (RIB, a selective CDK4/6 inhibitor) in combination with endocrine therapy (aromatase inhibitor [AI] or fulvestrant [FUL]) demonstrated a significant prolongation of overall survival among
Autor:
Anja Welt, Jacqueline Rauh, Arnd Nusch, Norbert Marschner, Lisa Kruggel, Mark-Oliver Zahn, Achim Wöckel, Nadia Harbeck, Martina Jänicke, Natalie Wetzel, Thomas Decker, Elmar Stickeler, Thomas Fietz, Marc Thill
Publikováno v:
Cancer Research. 81:PS11-16
Introduction Invasive lobular breast cancer (ILC) is with 5-10% the second most common histologic type of invasive breast cancer after invasive ductal breast cancer (IDC). ILC differs from IDC, for example in its metastatic pattern. However, guidelin
Autor:
Christoph Losem, Cornelius F. Waller, A. Hipper, Albrecht Stenzinger, C. Bernhardt, Parvis Sadjadian, Martina Jänicke, Norbert Marschner, Petros Christopoulos, Frank Griesinger, Martin Reck, L. Spring, Mike Thomas, A. Karatas, Achim Rittmeyer, M. Reiser, J. Sahlmann, A. Fleitz, Christian Grah, Wilko Weichert, Wolfgang Gleiber, Monika Heilmann, Arnd Nusch, Wilfried Eberhardt, Mark-Oliver Zahn, Lukas C. Heukamp, Reinhard Büttner, Christoph Maintz, Martin Sebastian
Publikováno v:
Lung Cancer. 152:174-184
Objectives An increasing number of treatment-determining biomarkers has been identified in non-small cell lung cancer (NSCLC) and molecular testing is recommended to enable optimal individualized treatment. However, data on implementation of these re
Autor:
Patrick Neven, Xavier Pivot, Antonia Ridolfi, Brad Lanoue, J. Thaddeus Beck, Guy Jerusalem, Arnd Nusch, Francisco J. Esteva, Giulia Bianchi, David Chandiwana, Miguel Martin, Karen Rodriguez Lorenc, Peter A. Fasching, Arlene Chan, Yingbo Wang, Michele De Laurentiis
Publikováno v:
The Breast : Official Journal of the European Society of Mastology
Breast, Vol 54, Iss, Pp 148-154 (2020)
Breast, Vol 54, Iss, Pp 148-154 (2020)
Purpose In the MONALEESA-3 Phase III trial of patients with hormone receptor–positive human epidermal growth factor receptor–negative advanced breast cancer, ribociclib plus fulvestrant significantly improved progression-free survival (PFS) and o
Autor:
Stephanie Dille, Richard A. Hansen, Johanna Harde, Karin Potthoff, Oliver Stötzer, Norbert Marschner, Ulrike Söling, Arnd Nusch
Publikováno v:
Clinical Breast Cancer. 20:e315-e326
Background There are only scarce data on treatment of elderly patients with nab-paclitaxel for metastatic breast cancer, especially from the real-world setting. Here we present data from the noninterventional study NABUCCO with special focus on taxan
Autor:
Jörg Schubert, Sherko Kümmel, Mattea Reinisch, Wolfgang Janni, Hans Tesch, Martin Schuler, Sara Y. Brucker, Diana Lüftner, Petra Krabisch, Christian M. Kurbacher, Tanja Fehm, Andreas Schneeweiss, Thomas Decker, Roswitha Fuchs, Andreas D. Hartkopf, Bernhard Heinrich, Peter A. Fasching, Arnd Nusch, Claudia Voges
Publikováno v:
Cancer Research. 80:P1-19
Introduction: RIBECCA is a national, multi-center, open-label, single-arm phase IIIb trial assessing the efficacy and safety of ribociclib in combination with letrozole in a patient population similar to the populations of MONALEESA-2, -3 and -7. Her
Autor:
Marco Chiabudini, Elmar Stickeler, Lisa Kruggel, Mark-Oliver Zahn, Achim Wöckel, Arnd Nusch, Martina Jänicke, Marc Thill, Thomas Decker, Anja Welt, Norbert Marschner, Nadia Harbeck
Publikováno v:
Cancer Research. 80:P2-17
Introduction Tumor Registries give insight into routine treatment and complement the knowledge derived from randomized controlled trials (RCT), since characteristics of patients from RCTs often differ from those of patients in routine care. Furthermo